FHD-286
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 144 patients (estimated)
- Sponsors
- Foghorn Therapeutics Inc.
- Tags
- BRG1 Inhibitor, BRM Inhibitor
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1860
- NCT Identifier
- NCT04891757
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.